Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06674343
What this trial is testing

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
Peking Union Medical College Hospital 144
Testing effectiveness (Phase 2)Study completedNCT04075396
What this trial is testing

Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Not applicableUnknownNCT00903292
What this trial is testing

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Non-Small Cell Lung Cancer
National Cheng-Kung University Hospital 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT06827145
What this trial is testing

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
National Cancer Center, China 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Testing effectiveness (Phase 2)UnknownNCT03457337
What this trial is testing

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Who this might be right for
Advanced NSCLC With EGFR Mutation
Henan Cancer Hospital 200
Testing effectiveness (Phase 2)Study completedNCT03736837
What this trial is testing

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT06062823
What this trial is testing

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

Who this might be right for
NSCLC
National University Hospital, Singapore 35
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Large-scale testing (Phase 3)Study completedNCT03924050
What this trial is testing

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 440
Testing effectiveness (Phase 2)Active Not RecruitingNCT03381274
What this trial is testing

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedImmune LLC 43
Large-scale testing (Phase 3)Looking for participantsNCT06350097
What this trial is testing

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 582
Early research (Phase 1)Study completedNCT01337765
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Unspecified Adult Solid Tumor, Protocol SpecificSolid Tumor
Pfizer 29
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Early research (Phase 1)Study completedNCT02228369
What this trial is testing

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
AstraZeneca 108
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05503888
What this trial is testing

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Who this might be right for
Relapsed or Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 160
Next Page